Inovio Pharmaceuticals (INO) Receivables - Other (2010 - 2023)

Inovio Pharmaceuticals has disclosed Receivables - Other across 14 years of filings, most recently posting $5.0 million for Q1 2023.

• In Q1 2023, Receivables - Other rose 41.77% year-over-year to $5.0 million; the TTM figure through Mar 2023 stood at $5.0 million (up 41.77% YoY), while the FY2022 annual figure was $10.0 million, up 178.79% from the prior year.
• Receivables - Other came in at $5.0 million for Q1 2023 at Inovio Pharmaceuticals, down from $9.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $12.9 million in Q2 2021 to a low of $425000.0 in Q4 2020.
• Average Receivables - Other over 5 years is $4.5 million, with a median of $2.9 million recorded in 2020.
• The largest YoY upside for Receivables - Other was 1413.72% in 2021 against a maximum downside of 69.42% in 2021.
• Over 5 years, Receivables - Other stood at $616000.0 in 2019, then slumped by 31.01% to $425000.0 in 2020, then soared by 511.76% to $2.6 million in 2021, then soared by 280.77% to $9.9 million in 2022, then tumbled by 49.88% to $5.0 million in 2023.
• Per Business Quant data, the three most recent Receivables - Other figures were $5.0 million in Q1 2023, $9.9 million in Q4 2022, and $7.6 million in Q3 2022.